ataprost and Coronary-Disease

ataprost has been researched along with Coronary-Disease* in 2 studies

Other Studies

2 other study(ies) available for ataprost and Coronary-Disease

Article	Year
[Experimental evaluation of a new prostacyclin analog (OP 41483) for myocardial protection]. Kyobu geka. The Japanese journal of thoracic surgery, 1986, Volume: 39, Issue:1 Topics: Animals; Coronary Disease; Dogs; Epoprostenol; Heart Arrest, Induced; Platelet Count; Prostaglandins, Synthetic; Vascular Resistance	1986
Vasodilator therapy with a new stable prostacyclin analog, OP-41483, for congestive heart failure due to coronary artery disease and comparison of hemodynamic effects and platelet aggregation with nitroprusside. The American journal of cardiology, 1986, Nov-01, Volume: 58, Issue:10 A new stable prostacyclin analog, OP-41483, was used in patients with severe congestive heart failure (CHF) due to coronary artery disease and compared with nitroprusside. During infusion of both drugs, mean brachial arterial pressure, total pulmonary resistance, pulmonary artery wedge pressure and systemic vascular resistance decreased significantly. Cardiac index and stroke index also increased significantly. Platelet aggregation did not change significantly during nitroprusside but decreased significantly with OP-41483 infusion. Thus, this analog may be useful for treatment of patients with CHF due to coronary artery disease. Topics: Aged; Coronary Disease; Epoprostenol; Female; Ferricyanides; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Nitroprusside; Platelet Aggregation; Prostaglandins, Synthetic	1986

Article

Year

[Experimental evaluation of a new prostacyclin analog (OP 41483) for myocardial protection].

Kyobu geka. The Japanese journal of thoracic surgery, 1986, Volume: 39, Issue:1

Topics: Animals; Coronary Disease; Dogs; Epoprostenol; Heart Arrest, Induced; Platelet Count; Prostaglandins, Synthetic; Vascular Resistance

1986

Vasodilator therapy with a new stable prostacyclin analog, OP-41483, for congestive heart failure due to coronary artery disease and comparison of hemodynamic effects and platelet aggregation with nitroprusside.

The American journal of cardiology, 1986, Nov-01, Volume: 58, Issue:10

A new stable prostacyclin analog, OP-41483, was used in patients with severe congestive heart failure (CHF) due to coronary artery disease and compared with nitroprusside. During infusion of both drugs, mean brachial arterial pressure, total pulmonary resistance, pulmonary artery wedge pressure and systemic vascular resistance decreased significantly. Cardiac index and stroke index also increased significantly. Platelet aggregation did not change significantly during nitroprusside but decreased significantly with OP-41483 infusion. Thus, this analog may be useful for treatment of patients with CHF due to coronary artery disease.

Topics: Aged; Coronary Disease; Epoprostenol; Female; Ferricyanides; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Nitroprusside; Platelet Aggregation; Prostaglandins, Synthetic

1986